Hen egg white bovine colostrum supplement reduces symptoms of mild/moderate COVID-19: a randomized control trial

Aim: The ability of a hen egg white bovine colostrum supplement to prevent severe COVID-19 was tested in a double-blind randomized control study. Methods: Adults with mild/moderate COVID-19, risk factors for severe disease, and within 5 days of symptom onset were assigned to the intervention (n = 77) or placebo (n = 79) arms. Symptoms were documented until day 42 post-enrollment and viral clearance was assessed at 11-13 days post-symptom onset. Results: One participant developed severe COVID-19. The severe-type symptom score was lower in the active arm at 11-13 days post-symptom onset (p = 0.049). Chest pain, fever/chills, joint pain/malaise, and sore throat were significantly less frequent in the active arm. No differences in viral clearance were observed. Conclusion: The intervention reduced symptoms of mild/moderate COVID-19

Radiopharmaceuticals drug interactions: a critical review

Radiopharmaceuticals play a critical role in modern medicine primarily for diagnostic purposes, but also for monitoring disease progression and response to treatment. As the use of image has been increased, so has the use of prescription medications. These trends increase the risk of interactions between medications and radiopharmaceuticals. These interactions which have an impact on image by competing with the radiopharmaceutical for binding sites for example can lead to false negative results. Drugs that accelerate the metabolism of the radiopharmaceutical can have a positive impact (i.e. speeding its clearance) or, if repeating image is needed, a negative impact. In some cases, for example in cardiac image among patients taking doxirubacin, these interactions may have a therapeutic benefit. The incidence of drug-radiopharmaceuticals adverse reactions is unknown, since they may not be reported or even recognized. Here,we compiled the medical literature, using the criteria of a systematic review established by the Cochrane Collaboration, on pharmaceutical-drug interactions to provide a summary of documented interactions by organ system and radiopharmaceuticals. The purpose is to provide a reference on drug interactions that could inform the nuclear medicine staff in their daily routine. Efforts to increase adverse event reporting, and ideally consolidate reports worldwide, can provide a critically needed resource for prevention of drug-radiopharmaceuticals interactions.<br>Os radiofármacos desempenham função crítica na medicina moderna, primariamente para fins diagnósticos, mas também no monitoramento da progressão de doenças assim como na avaliação de respostas ao tratamento. O uso da tecnologia por imagem tem crescido e conseqüentemente as prescrições de medicamentos (radiofármacos em especial) com esse propósito. Este fato, aumenta o risco de interações entre medicamentos e radiofármacos. Interações que podem ter um impacto na imagem, podem resultar em falso negativo e assim ter sérias conseqüências para o paciente. Já drogas que aceleram o metabolismo podem ter resultado positivo pois podem aumentar a taxa de eliminação do radiofármaco (clearance acelerado). Contudo, podem ainda ter resultados negativos, se a interação resultar em necessidade de repetição do exame. Em alguns casos, por exemplo em imagem cardíaca, entre pacientes sob o uso de doxarubicina, essas interações podem ter efeito terapêutico. A incidência de efeitos adversos envolvendo radiofármacos é desconhecida, além de não ser oficialmente reconhecida, nem notificada, principalmente no Brasil. Nesse estudo foram compilados da literatura médica, usando a metodologia da revisão sistemática, estabelecida pela Cochrane Collaboration, estudos e relatos de interações medicamentosas com radiofármacos. O objetivo é prover uma referência (sumário) de interações medicametosas com radiofármacos que possa auxiliar a medicina nuclear na sua rotina diária. Contudo, esforços devem ser feitos na tentativa de instituir a notificação de efeitos adversos com radiofármacos, e assim prevenir esse tipo de interação

The CMS experiment at the CERN LHC

0info:eu-repo/semantics/publishe